<DOC>
	<DOCNO>NCT00082797</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy , methotrexate , work different way stop tumor cell divide stop grow die . Leucovorin may decrease side effect cause high-dose methotrexate . PURPOSE : This phase II trial study well give high-dose methotrexate together leucovorin work treat patient newly diagnose glioblastoma multiforme .</brief_summary>
	<brief_title>High-Dose Methotrexate Leucovorin Treating Patients With Newly Diagnosed Glioblastoma Multiforme</brief_title>
	<detailed_description>OBJECTIVES : Primary - Determine response patient newly diagnose glioblastoma multiforme treat high-dose methotrexate leucovorin calcium . Secondary - Determine acute toxicity regimen patient . - Determine duration survival patient treat regimen . OUTLINE : This multicenter study . Patients receive high-dose methotrexate IV 4 hour day 1 oral IV leucovorin calcium every 6 hour begin day 2 continue blood methotrexate level acceptable . Treatment repeat every 14 day 6 course absence disease progression unacceptable toxicity . Patients receive standard radiotherapy without chemotherapy . Patients disease progression proceed standard radiotherapy without chemotherapy upon stop methotrexate therapy . Patients follow 30 day every 2 month 2 year . PROJECTED ACCRUAL : A total 19-36 patient accrue study .</detailed_description>
	<mesh_term>Glioblastoma</mesh_term>
	<mesh_term>Nervous System Neoplasms</mesh_term>
	<mesh_term>Central Nervous System Neoplasms</mesh_term>
	<mesh_term>Methotrexate</mesh_term>
	<mesh_term>Levoleucovorin</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically confirm glioblastoma multiforme ( GBM ) Supratentorial grade IV disease Measurable contrastenhancing disease ≥ 1 cm CT scan MRI No radiographic evidence ascites pleural effusion PATIENT CHARACTERISTICS : Age 18 Performance status ECOG 02 Life expectancy Not specify Hematopoietic Absolute neutrophil count ≥ 1,500/mm^3 Platelet count ≥ 100,000/mm^3 Hepatic SGOT ≤ 4.0 time upper limit normal Bilirubin ≤ 2.0 mg/dL Renal Creatinine ≤ 2.0 mg/dL Creatinine clearance ≥ 50 mL/min Cardiovascular No uncontrolled hypertension No unstable angina No symptomatic congestive heart failure No uncontrolled cardiac arrhythmia No myocardial infarction within past 6 month Other Not pregnant nursing Negative pregnancy test Fertile patient must use effective contraception Able achieve hydration No diabetes insipidus No known hypersensitivity methotrexate leucovorin calcium No concurrent serious infection medical illness would preclude study participation No malignancy within past 2 year except basal cell squamous cell skin cancer carcinoma situ cervix PRIOR CONCURRENT THERAPY : Biologic therapy No prior immunotherapy GBM No prior administration follow biologic agent GBM : Immunotoxins Immunoconjugates Antisense therapy Peptide receptor antagonist Interferons Interleukins Tumorinfiltrating lymphocyte Lymphokineactivated killer cell Gene therapy No concurrent prophylactic growth factor ( e.g. , filgrastim [ GCSF ] sargramostim [ GMCSF ] ) Chemotherapy No prior chemotherapy GBM No concurrent chemotherapy Endocrine therapy Prior glucocorticoid therapy allow No prior hormonal therapy GBM Patients must maintain stable corticosteroid regimen least 1 week Radiotherapy No prior cranial irradiation No prior radiotherapy GBM Surgery Recovered prior surgery Other At least 1 week since prior treatment follow : Salicylates Nonsteroidal antiinflammatory drug Sulfonamide medication Vitamin C No concurrent investigational agent</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2010</verification_date>
	<keyword>adult glioblastoma</keyword>
	<keyword>adult giant cell glioblastoma</keyword>
	<keyword>adult gliosarcoma</keyword>
</DOC>